https://www.selleckchem.com/pr....oducts/Clopidogrel-b
Standard-of-care treatment for metastatic hormone receptor-positive (HR ), HER2-negative (HER2 ) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progression on CDK4/6i is unknown. The TRINITI-1 trial investigated ribociclib, a CDK4/6i that has recently demonstrated significant overall survival benefit in two phase III trials, in combination with everolimus and exemestane in patients with HR , HER2 advanced breast cancer (ABC) after progr
Like
Comment
Share
